Regimen Reference Order – riTUXimab desensitization

riTUXimab desensitization protocol is prescribed in combination with a riTUXimab-based protocol

ARIA: LYMP - [riTUX desens. q7d]
LYMP - [riTUX desens. q21d]
LYMP - [riTUX desens. q28d]
LYMP - [riTUX desens. maintenance]

Planned Course: **Refer to prescribed riTUXimab-based protocol**
Indication for Use: **Eligible patients with previous hypersensitivity reactions to riTUXimab**

Alert: Desensitization protocol

riTUXimab:

- ***riTUXimab is prepared to a final concentration of 1 mg/mL by Pharmacy***
- ***riTUXimab must be the first chemotherapy agent administered when given in combination with another chemotherapy agent***
- ***IV tubing is primed with riTUXimab***
- ***riTUXimab is administered slowly following specified rate increases***
- ***riTUXimab administration duration depends upon total dose. riTUXimab infusion can take up to 7 hours to complete***

CVAD: At Provider's Discretion

Proceed with treatment if:

- ***Refer to prescribed riTUXimab-based protocol***

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements

Drug	Dose	CCMB Administration Guideline
Refer to prescribed riTUXimab-based protocol		

Treatment Regimen – riTUXimab desensitization

Establish primary solution 500 mL of: normal saline

Drug	Dose	CCMB Administration Guideline
cetirizine	20 mg	Orally **1 hour** prior to riTUXimab
acetaminophen	650 mg	Orally **1 hour** prior to riTUXimab

dexamethasone	20 to 40 mg	IV in normal saline 50 mL over 15 minutes **1 hour** prior to rituximab **Nursing Alert: riTUXimab starts **1 hour after completion** of dexamethasone infusion*
famotidine	20 mg	IV in normal saline 50 mL over 15 minutes **45 minutes** prior to riTUXimab
Wait 45 minutes after completion of IV pre-medication(s) before starting riTUXimab		
riTUXimab (brand name specific)	Dose as specified in protocol	IV in normal saline made up to a final concentration of 1 mg/mL following the administration rates below: ***Step 1***: 2 mL/hour for 15 minutes, then ***Step 2***: 4 mL/hour 15 minutes, then ***Step 3***: 6 mL/hour for 15 minutes, then ***Step 4***: 8 mL/hour for 15 minutes, then ***Step 5***: 10 mL/hour 15 minutes, then ***Step 6***: 15 mL/hour for 15 minutes, then ***Step 7***: 30 mL/hour for 15 minutes, then ***Step 8***: 60 mL/hour for 15 minutes, then ***Step 9***: 80 mL/hour for 15 minutes, then ***Step 10***: 100 mL/hour for 15 minutes, then ***Step 11***: 120 mL/hour for 15 minutes, then ***Step 12***: 140 mL/hour for 15 minutes, then ***Step 13***: 160 mL/hour for 15 minutes, then ***Step 14***: 180 mL/hour for 15 minutes, then ***Step 15***: 200 mL/hour until infusion is complete **Alert: Pharmacy to ensure final volume on label* **Alert: riTUXimab must be the first agent administered when given in combination with another chemotherapy agent* **Nursing Alert: IV tubing is primed with riTUXimab* **Alert: Ensure brand name on prescription label (indicated in brackets on prescription label) matches prescribed order* **Nursing Alert: There is no interruption in riTUXimab infusion unless patient is experiencing an infusion-related reaction*

In the event of an infusion-related hypersensitivity reaction, refer to the **'Hypersensitivity Reaction Standing Order'**

REQUIRED MONITORING

- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O_2 saturation) prior to each riTUXimab infusion and as clinically indicated
- No observation period is required. Patient can be discharged from treatment room if stable whether they have had a reaction or not
- Refer to the prescribed riTUXimab-based protocol for additional monitoring

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
Refer to the prescribed riTUXimab-based protocol		

DISCHARGE INSTRUCTIONS

- Patients should be instructed to contact their cancer team immediately if symptoms of hypersensitivity reactions occur after discharge
- Refer to the prescribed riTUXimab-based protocol for additional discharge instructions

ADDITIONAL INFORMATION

- Once the patient requires riTUXimab desensitization protocol, all subsequent **riTUXimab doses must be given using riTUXimab desensitization protocol**
- Hematologist must write first prescription of riTUXimab desensitization protocol
- Administering nurse must document any infusion-related reactions with any dose of riTUXimab
- Refer to the prescribed riTUXimab-based protocol for additional riTUXimab information
- Due to the duration of treatment, administration site restrictions may be in place
- Intravenous riTUXimab is available from more than one manufacturer and uses several different brand names. Brand name will be indicated in brackets after riTUXimab. **Ensure prescription label matches the brand name on prescribed order**
- Support protocols are available under **riTUX desens. q7d**, **riTUX desens. q21d**, **riTUX desens. q28d** and **riTUX desens. maint.** in the "Lymphoma" folder